Aeglea BioTherapeutics Revenue | AGLE

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Aeglea BioTherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	886 K	2.33 M	18.7 M	21.8 K	-	3.89 M	5.2 M	4.63 M	6.08 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
18.7 M	21.8 K	5.22 M

Quarterly Revenue Aeglea BioTherapeutics

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	688 K	198 K	-	174 K	625 K	1.36 M	-	1.4 M	13.7 M	-	-	-	-	-	-	-	-	-	-	-	2.38 M	1.51 M	1.48 M	1.26 M	1.48 M	982 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.7 M	174 K	2.1 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Sigilon Therapeutics SGTX	12.9 M	-	-	$ 728 M	USA
Orgenesis ORGS	1.04 M	-	-33.86 %	$ 61.2 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
SIGA Technologies SIGA	94.6 M	$ 3.12	-0.95 %	$ 223 M	USA
TRACON Pharmaceuticals TCON	12 M	-	-1.38 %	$ 46.8 M	USA
Revance Therapeutics RVNC	234 M	-	-	$ 309 M	USA
Sierra Oncology SRRA	300 K	-	-0.05 %	$ 1.34 B	Canada
Atea Pharmaceuticals AVIR	351 M	$ 4.04	-0.25 %	$ 329 M	USA
Soligenix SNGX	119 K	$ 0.37	0.14 %	$ 1.92 M	USA
Sanofi SNY	37.4 B	$ 41.6	-0.86 %	$ 50.8 B	France
Collegium Pharmaceutical COLL	205 M	$ 22.96	-2.3 %	$ 727 M	USA
Vaccinex VCNX	601 K	-	-61.37 %	$ 654 K	USA
Nymox Pharmaceutical Corporation NYMX	5 K	-	-19.68 %	$ 18.4 M	Canada
Spruce Biosciences SPRB	4.91 M	$ 45.15	-1.85 %	$ 34.6 M	USA
Spero Therapeutics SPRO	66.8 M	$ 1.11	-1.77 %	$ 62.2 M	USA
Curis CRIS	9.44 M	$ 0.39	-4.59 %	$ 5.13 M	USA
Forma Therapeutics Holdings FMTX	7.44 M	-	-	$ 958 M	USA
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
Blueprint Medicines Corporation BPMC	509 M	-	-	$ 8.14 B	USA
Sarepta Therapeutics SRPT	443 M	$ 17.73	-2.48 %	$ 1.78 B	USA
CytomX Therapeutics CTMX	76.2 M	$ 2.32	-4.92 %	$ 320 M	USA
Paratek Pharmaceuticals PRTK	160 M	-	-	$ 121 M	USA
Supernus Pharmaceuticals SUPN	719 M	$ 40.7	-3.26 %	$ 2.3 B	USA
ASLAN Pharmaceuticals Limited ASLN	3 M	-	-14.27 %	$ 1.7 M	Singapore
Savara SVRA	257 K	$ 4.22	-7.05 %	$ 938 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
China SXT Pharmaceuticals SXTC	1.14 M	$ 0.04	-14.58 %	$ 27.2 K	China
Ampio Pharmaceuticals AMPE	469 K	-	-11.43 %	$ 502 K	USA
Takeda Pharmaceutical Company Limited TAK	4.58 T	$ 20.24	-0.66 %	$ 32 B	Japan
Tarsus Pharmaceuticals TARS	451 M	$ 68.2	-5.38 %	$ 2.85 B	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Bio-Techne Corporation TECH	1.22 B	$ 72.55	-0.1 %	$ 11.3 B	USA
Nabriva Therapeutics plc NBRV	36.9 M	-	-	$ 4.55 M	Irlanda
NGM Biopharmaceuticals NGM	4.42 M	-	-	$ 127 M	USA
Unity Biotechnology UBX	236 K	-	-33.41 %	$ 3.37 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Titan Pharmaceuticals TTNP	184 K	-	-3.76 %	$ 3.47 M	USA
iTeos Therapeutics ITOS	35 M	-	-	$ 411 M	USA
Tenax Therapeutics TENX	49.3 K	$ 1.72	-2.27 %	$ 67.5 M	USA
Teva Pharmaceutical Industries Limited TEVA	1.5 B	$ 39.41	-1.95 %	$ 45.1 B	Israel
CymaBay Therapeutics CBAY	31.1 M	-	-	$ 3.45 B	USA
TFF Pharmaceuticals TFFP	734 K	-	-60.05 %	$ 125 K	USA
Theratechnologies THTX	85.9 M	-	-	$ 83.9 M	Canada
Timber Pharmaceuticals TMBR	83.2 K	-	-	$ 717 K	USA
TG Therapeutics TGTX	616 M	$ 54.17	1.9 %	$ 7.82 B	USA